Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.32 |
| ▸ | CTSV | O60911 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115882 | 1.00 | BTK (0.35) | BTKCTSLHDAC4HDAC1HDAC6 | |
| SCHEMBL13048217 | 1.00 | BTK (0.35) | BTKCTSLHDAC4HDAC1HDAC6 | |
| SCHEMBL2622110 | 0.92 | AAK1 (0.35) | CTSLHDAC4HDAC1HDAC6AAK1 | |
| SCHEMBL2113517 | 0.92 | AAK1 (0.35) | CTSLHDAC4HDAC1HDAC6AAK1 | |
| SCHEMBL13049348 | 0.86 | AAK1 (0.33) | CTSLHDAC4HDAC1HDAC6AAK1 | |
| SCHEMBL2113969 | 0.85 | — | — | |
| SCHEMBL2622099 | 0.85 | — | — | |
| SCHEMBL2117361 | 0.85 | XIAP (0.42) | CTSLCTSKGAA | |
| SCHEMBL2622112 | 0.85 | XIAP (0.42) | CTSLCTSKGAA | |
| SCHEMBL17577899 | 0.85 | XIAP (0.42) | CTSLCTSKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274278-A1 | IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274278-A1 | IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010138496-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274278-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | BTK 4310/4885CTSL 134/4885HDAC4 2234/4885 |
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | BTK 4310/4885CTSL 134/4885HDAC4 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.